{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T21:45:46Z","timestamp":1788385546710,"version":"build-2803163510"},"reference-count":60,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002426","name":"Fondazione Telethon","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002426","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013918","name":"Sanfilippo Children's Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013918","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018232","name":"University of Pennsylvania The Orphan Disease Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018232","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.ymthe.2024.09.030","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T21:00:50Z","timestamp":1727470850000},"page":"4108-4121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Anti-amyloid treatment is broadly effective in neuronopathic mucopolysaccharidoses and synergizes with gene therapy in MPS-IIIA"],"prefix":"10.1016","volume":"32","author":[{"given":"Marianna","family":"Giaccio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Monaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Galiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Parente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Borzacchiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Rubino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank-Gerrit","family":"Kl\u00e4rner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Killa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Perna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Piccolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Marotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefang","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Khijniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrar","family":"Siddique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Schrader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey V.","family":"Pshezhetsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolina Cristina","family":"Sorrentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gal","family":"Bitan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Fraldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2024.09.030_bib1","doi-asserted-by":"crossref","DOI":"10.1017\/S1462399408000550","article-title":"The mucopolysaccharidoses: a success of molecular medicine","volume":"10","author":"Clarke","year":"2008","journal-title":"Expert Rev. Mol. Med."},{"key":"10.1016\/j.ymthe.2024.09.030_bib2","series-title":"The Metabolic and Molecular Bases of Inherited Disease","author":"Neufeld","year":"2001"},{"key":"10.1016\/j.ymthe.2024.09.030_bib3","first-page":"S34","article-title":"Disease pathogenesis explained by basic science: lysosomal storage diseases as autophagocytic disorders","volume":"47","author":"Ballabio","year":"2009","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ymthe.2024.09.030_bib4","doi-asserted-by":"crossref","first-page":"719","DOI":"10.4161\/auto.19469","article-title":"Autophagy in lysosomal storage disorders","volume":"8","author":"Lieberman","year":"2012","journal-title":"Autophagy"},{"key":"10.1016\/j.ymthe.2024.09.030_bib5","doi-asserted-by":"crossref","first-page":"113","DOI":"10.4161\/auto.5227","article-title":"Lysosomal storage diseases as disorders of autophagy","volume":"4","author":"Settembre","year":"2008","journal-title":"Autophagy"},{"key":"10.1016\/j.ymthe.2024.09.030_bib6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s12017-019-08559-1","article-title":"Mucopolysaccharidosis and Autophagy: Controversies on the Contribution of the\u00a0Process to the Pathogenesis and Possible Therapeutic Applications","volume":"22","author":"Pierzynowska","year":"2020","journal-title":"Neuromolecular Med."},{"key":"10.1016\/j.ymthe.2024.09.030_bib7","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.ymthe.2020.02.005","article-title":"The Amyloid Inhibitor CLR01 Relieves Autophagy and Ameliorates Neuropathology in a Severe Lysosomal Storage Disease","volume":"28","author":"Monaco","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.09.030_bib8","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13052-018-0565-y","article-title":"Gene therapy for mucopolysaccharidoses: in\u00a0vivo and ex\u00a0vivo approaches","volume":"44","author":"Fraldi","year":"2018","journal-title":"Ital. J. Pediatr."},{"key":"10.1016\/j.ymthe.2024.09.030_bib9","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.1016\/j.bbmt.2019.02.012","article-title":"Hematopoietic Stem Cell Transplantation for Mucopolysaccharidoses: Past, Present, and Future","volume":"25","author":"Taylor","year":"2019","journal-title":"Biol. Blood Marrow Transpl."},{"key":"10.1016\/j.ymthe.2024.09.030_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/diseases7030047","article-title":"Cell and Gene Therapies for Mucopolysaccharidoses: Base Editing and Therapeutic Delivery to the CNS","volume":"7","author":"Christensen","year":"2019","journal-title":"Diseases"},{"key":"10.1016\/j.ymthe.2024.09.030_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21020400","article-title":"Novel Enzyme Replacement Therapies for Neuropathic Mucopolysaccharidoses","volume":"21","author":"Sato","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2024.09.030_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22179200","article-title":"Gene Therapy for Neuronopathic Mucopolysaccharidoses: State of the Art","volume":"22","author":"de Castro","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2024.09.030_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.965089","article-title":"Delivering gene therapy for mucopolysaccharide diseases","volume":"9","author":"Wood","year":"2022","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.ymthe.2024.09.030_bib14","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1089\/hum.2019.217","article-title":"In\u00a0Vivo Gene Therapy for Mucopolysaccharidosis Type III (Sanfilippo Syndrome): A New Treatment Horizon","volume":"30","author":"Marc\u00f2","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2024.09.030_bib15","article-title":"In\u00a0vivo Gene Therapy to the Liver and Nervous System: Promises and Challenges","volume":"8","author":"Cantore","year":"2021","journal-title":"Front. Med."},{"key":"10.1016\/j.ymthe.2024.09.030_bib16","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1089\/hum.2013.238","article-title":"Intracerebral administration of adeno-associated viral vector serotype rh.10 carrying human SGSH and SUMF1 cDNAs in children with mucopolysaccharidosis type IIIA disease: results of a phase I\/II trial","volume":"25","author":"Tardieu","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2024.09.030_bib17","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S1474-4422(17)30169-2","article-title":"Intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome: an uncontrolled phase 1\/2 clinical trial","volume":"16","author":"Tardieu","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymthe.2024.09.030_bib18","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/jimd.12316","article-title":"Novel therapies for mucopolysaccharidosis type III","volume":"44","author":"Seker Yilmaz","year":"2021","journal-title":"J.\u00a0Inherit. Metab. Dis."},{"key":"10.1016\/j.ymthe.2024.09.030_bib19","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/hum.2018.015","article-title":"Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN","volume":"29","author":"Hinderer","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2024.09.030_bib20","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/1471-2377-13-174","article-title":"Blood-brain barrier impairment in MPS III patients","volume":"13","author":"Garbuzova-Davis","year":"2013","journal-title":"BMC Neurol."},{"key":"10.1016\/j.ymthe.2024.09.030_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2018.12.163","article-title":"EMPOWERS: A phase 1\/2 clinical trial of SB-318 ZFN-mediated in\u00a0vivo human genome editing for treatment of MPS I (Hurler syndrome)","volume":"126","author":"Harmatz","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2024.09.030_bib22","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1097\/00005072-199908000-00004","article-title":"Accumulation of intracellular amyloid-\u03b2 peptide (A \u03b2 1-40) in mucopolysaccharidosis brains","volume":"58","author":"Ginsberg","year":"1999","journal-title":"J.\u00a0Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.ymthe.2024.09.030_bib23","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s00401-007-0325-3","article-title":"Mechanisms of neurodegeneration in mucopolysaccharidoses II and IIIB: analysis of human brain tissue","volume":"115","author":"Hamano","year":"2008","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.ymthe.2024.09.030_bib24","article-title":"Brain Pathology in Mucopolysaccharidoses (MPS) Patients with Neurological Forms","volume":"9","author":"Viana","year":"2020","journal-title":"J.\u00a0Clin. Med."},{"key":"10.1016\/j.ymthe.2024.09.030_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21041459","article-title":"Cathepsin B-associated Activation of Amyloidogenic Pathway in Murine Mucopolysaccharidosis Type I Brain Cortex","volume":"21","author":"Viana","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2024.09.030_bib26","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.expneurol.2017.06.010","article-title":"Axonal dystrophy in the brain of mice with Sanfilippo syndrome","volume":"295","author":"Beard","year":"2017","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ymthe.2024.09.030_bib27","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201911185","article-title":"Haematopoietic stem cell gene therapy with IL-1Ra rescues cognitive loss in mucopolysaccharidosis IIIA","volume":"12","author":"Parker","year":"2020","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ymthe.2024.09.030_bib28","doi-asserted-by":"crossref","first-page":"112","DOI":"10.15252\/emmm.201606965","article-title":"Lysosomal dysfunction disrupts presynaptic maintenance and restoration of presynaptic function prevents neurodegeneration in lysosomal storage diseases","volume":"9","author":"Sambri","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ymthe.2024.09.030_bib29","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.ymthe.2022.01.037","article-title":"Fluoxetine ameliorates mucopolysaccharidosis type IIIA","volume":"30","author":"Capuozzo","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.09.030_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0027461","article-title":"Defects in the medial entorhinal cortex and dentate gyrus in the mouse model of Sanfilippo syndrome type B","volume":"6","author":"Ohmi","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2024.09.030_bib31","doi-asserted-by":"crossref","first-page":"14870","DOI":"10.1073\/pnas.1416660111","article-title":"Delivery of an enzyme-IGFII fusion protein to the mouse brain is therapeutic for mucopolysaccharidosis type IIIB","volume":"111","author":"Kan","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2024.09.030_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0080142","article-title":"Amyloidosis, synucleinopathy, and prion encephalopathy in a neuropathic lysosomal storage disease: the CNS-biomarker potential of peripheral blood","volume":"8","author":"Naughton","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2024.09.030_bib33","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1093\/brain\/awu355","article-title":"Neuroinflammation, mitochondrial defects and neurodegeneration in mucopolysaccharidosis III type C mouse model","volume":"138","author":"Martins","year":"2015","journal-title":"Brain"},{"key":"10.1016\/j.ymthe.2024.09.030_bib34","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1093\/glycob\/9.12.1389","article-title":"A mouse model for mucopolysaccharidosis type III A (Sanfilippo syndrome)","volume":"9","author":"Bhaumik","year":"1999","journal-title":"Glycobiology"},{"key":"10.1016\/j.ymthe.2024.09.030_bib35","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3389\/fnmol.2020.00037","article-title":"Protein Aggregation and Dysfunction of Autophagy-Lysosomal Pathway: A Vicious Cycle in Lysosomal Storage Diseases","volume":"13","author":"Monaco","year":"2020","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.ymthe.2024.09.030_bib36","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.2174\/13816128113199990496","article-title":"Disrupting self-assembly and toxicity of amyloidogenic protein oligomers by \"molecular tweezers\" - from the test tube to animal models","volume":"20","author":"Attar","year":"2014","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ymthe.2024.09.030_bib37","doi-asserted-by":"crossref","first-page":"11318","DOI":"10.1039\/C6CC04640A","article-title":"Molecular tweezers for lysine and arginine - powerful inhibitors of pathologic protein aggregation","volume":"52","author":"Schrader","year":"2016","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ymthe.2024.09.030_bib38","doi-asserted-by":"crossref","first-page":"657","DOI":"10.3389\/fchem.2019.00657","article-title":"Molecular Lysine Tweezers Counteract Aberrant Protein Aggregation","volume":"7","author":"Hadrovic","year":"2019","journal-title":"Front. Chem."},{"key":"10.1016\/j.ymthe.2024.09.030_bib39","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1124\/pharmrev.122.000654","article-title":"Molecular Tweezers: Supramolecular Hosts with Broad-Spectrum Biological Applications","volume":"75","author":"Shahpasand-Kroner","year":"2023","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ymthe.2024.09.030_bib40","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1038\/s42003-021-02603-2","article-title":"Lysine-selective molecular tweezers are cell penetrant and concentrate in lysosomes","volume":"4","author":"Li","year":"2021","journal-title":"Commun. Biol."},{"key":"10.1016\/j.ymthe.2024.09.030_bib41","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1172\/JCI66778","article-title":"Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy","volume":"123","author":"Haurigot","year":"2013","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2024.09.030_bib42","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.omtm.2019.10.009","article-title":"Enhancing the Therapeutic Potential of Sulfamidase for the Treatment of Mucopolysaccharidosis IIIA","volume":"15","author":"Sorrentino","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2024.09.030_bib43","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/jnc.14632","article-title":"The role of innate immunity in mucopolysaccharide diseases","volume":"148","author":"Parker","year":"2019","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.ymthe.2024.09.030_bib44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035787","article-title":"Neuropathology in mouse models of mucopolysaccharidosis type I, IIIA and IIIB","volume":"7","author":"Wilkinson","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2024.09.030_bib45","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/emmm.201202083","article-title":"A highly secreted sulphamidase engineered to cross the blood-brain barrier corrects brain lesions of mice with mucopolysaccharidoses type IIIA","volume":"5","author":"Sorrentino","year":"2013","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ymthe.2024.09.030_bib46","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1038\/s41467-021-23903-5","article-title":"Altered heparan sulfate metabolism during development triggers dopamine-dependent autistic-behaviours in models of lysosomal storage disorders","volume":"12","author":"De Risi","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2024.09.030_bib47","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.3390\/molecules20022510","article-title":"The effect of glycosaminoglycans (GAGs) on amyloid aggregation and toxicity","volume":"20","author":"Iannuzzi","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.ymthe.2024.09.030_bib48","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/2050-6511-15-23","article-title":"Safety and pharmacological characterization of the molecular tweezer CLR01\u00a0\u2013 a broad-spectrum inhibitor of amyloid proteins' toxicity","volume":"15","author":"Attar","year":"2014","journal-title":"BMC Pharmacol. Toxicol."},{"key":"10.1016\/j.ymthe.2024.09.030_bib49","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/mt.2015.212","article-title":"A Comprehensive Map of CNS Transduction by Eight Recombinant Adeno-associated Virus Serotypes Upon Cerebrospinal Fluid Administration in Pigs","volume":"24","author":"Sorrentino","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.09.030_bib50","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s43441-023-00599-x","article-title":"Detection, Monitoring, and Mitigation of Drug-Induced Nephrotoxicity: A Pragmatic Approach","volume":"58","author":"Antognini","year":"2024","journal-title":"Ther. Innov. Regul. Sci."},{"key":"10.1016\/j.ymthe.2024.09.030_bib51","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/hmg\/6.4.503","article-title":"Murine mucopolysaccharidosis type I: targeted disruption of the murine alpha-L-iduronidase gene","volume":"6","author":"Clarke","year":"1997","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2024.09.030_bib52","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1073\/pnas.252784899","article-title":"Activated microglia in cortex of mouse models of mucopolysaccharidoses I and IIIB","volume":"100","author":"Ohmi","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2024.09.030_bib53","doi-asserted-by":"crossref","first-page":"14505","DOI":"10.1073\/pnas.96.25.14505","article-title":"Mouse model of Sanfilippo syndrome type B produced by targeted disruption of the gene encoding alpha-N-acetylglucosaminidase","volume":"96","author":"Li","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2024.09.030_bib54","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0000772","article-title":"Development of sensory, motor and behavioral deficits in the murine model of Sanfilippo syndrome type B","volume":"2","author":"Heldermon","year":"2007","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2024.09.030_bib55","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1038\/s41591-024-03079-3","article-title":"Anakinra in Sanfilippo syndrome: a phase 1\/2 trial","volume":"30","author":"Polgreen","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2024.09.030_bib56","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1093\/brain\/aws289","article-title":"Protection of primary neurons and mouse brain from Alzheimer's pathology by molecular tweezers","volume":"135","author":"Attar","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.ymthe.2024.09.030_bib57","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/978-1-4939-7811-3_24","article-title":"Using Molecular Tweezers to Remodel Abnormal Protein Self-Assembly and Inhibit the Toxicity of Amyloidogenic Proteins","volume":"1777","author":"Malik","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ymthe.2024.09.030_bib58","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13195-020-00743-x","article-title":"The molecular tweezer CLR01 improves behavioral deficits and reduces tau pathology in P301S-tau transgenic mice","volume":"13","author":"Di","year":"2021","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.ymthe.2024.09.030_bib59","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1038\/s41467-020-18689-x","article-title":"CLR01 protects dopaminergic neurons in\u00a0vitro and in mouse models of Parkinson\u2019s disease","volume":"11","author":"Bengoa-Vergniory","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2024.09.030_bib60","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.bbr.2004.08.019","article-title":"Development of motor deficits in a murine model of mucopolysaccharidosis type IIIA (MPS-IIIA)","volume":"158","author":"Hemsley","year":"2005","journal-title":"Behav. Brain Res."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001624006543?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001624006543?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:29:31Z","timestamp":1783020571000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001624006543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":60,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S1525001624006543"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.09.030","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-amyloid treatment is broadly effective in neuronopathic mucopolysaccharidoses and synergizes with gene therapy in MPS-IIIA","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.09.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}